We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) HCV Therapy Application Validated in Europe
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced that its Marketing Authorization Application (MAA) for experimental direct-acting antiviral (DAA) of once-daily, single tablet regimen (STR) of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients has been fully validated.
Shares of Gilead have underperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year with the stock losing 21.6% during this period, compared with the industry’s decline of 12.8%.
The application is under assessment by the European Medicines Agency (EMA).The application will be reviewed by the EMA under an accelerated procedure given the need for advanced HCV treatments.
We remind investors that in Dec 2016 the company had filed a regulatory application in the U.S., seeking approval for a once-daily fixed-dose combination of Sovaldi/velpatasvir plus voxilaprevir for the treatment of DAA-experienced chronic HCV-infected patients.
Gilead is known for its presence in the HCV market because of its blockbuster drugs, Sovaldi and Harvoni. The HCV portfolio got a huge a boost when Epclusa gained approval in both the U.S. and the EU in 2016 to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection.
Gilead is working on bringing new HCV therapies to market. If the DAA is approved, the combination would be the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors.
However, we note that Gilead’s HCV treatments face competition from AbbVie’s (ABBV - Free Report) Viekira Pak and Viekira XR, Bristol-Myers’ (BMY - Free Report) Daklinza among others.
Gilead Sciences currently carries a Zacks Rank #3 (Hold).
Sucampo’s estimates increased from $1.58 to $1.74 for 2017 over the last 30 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead (GILD) HCV Therapy Application Validated in Europe
Gilead Sciences, Inc. (GILD - Free Report) announced that its Marketing Authorization Application (MAA) for experimental direct-acting antiviral (DAA) of once-daily, single tablet regimen (STR) of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients has been fully validated.
Shares of Gilead have underperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year with the stock losing 21.6% during this period, compared with the industry’s decline of 12.8%.
The application is under assessment by the European Medicines Agency (EMA).The application will be reviewed by the EMA under an accelerated procedure given the need for advanced HCV treatments.
We remind investors that in Dec 2016 the company had filed a regulatory application in the U.S., seeking approval for a once-daily fixed-dose combination of Sovaldi/velpatasvir plus voxilaprevir for the treatment of DAA-experienced chronic HCV-infected patients.
Gilead is known for its presence in the HCV market because of its blockbuster drugs, Sovaldi and Harvoni. The HCV portfolio got a huge a boost when Epclusa gained approval in both the U.S. and the EU in 2016 to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection.
Gilead is working on bringing new HCV therapies to market. If the DAA is approved, the combination would be the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors.
However, we note that Gilead’s HCV treatments face competition from AbbVie’s (ABBV - Free Report) Viekira Pak and Viekira XR, Bristol-Myers’ (BMY - Free Report) Daklinza among others.
Gilead Sciences currently carries a Zacks Rank #3 (Hold).
Gilead Sciences Inc. Price and Consensus
Gilead Sciences Inc. Price and Consensus | Gilead Sciences Inc. Quote
Key Picks
A better-ranked stock in this industry is Sucampo Pharmaceuticals . The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s estimates increased from $1.58 to $1.74 for 2017 over the last 30 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>